Corrigendum to: Identification of Potential Anticancer Activities of Novel Ganoderma lucidum Extracts Using Gene Expression and Pathway Network Analysis (Genomics Insights, (2016), 9, (1-16), 10.4137/GEI.S32477);Identification of potential anticancer activities of novel ganoderma lucidum extracts using gene expression and pathway network analysis

Genomics Insights

Volumn 9, Issue , 2016, Pages 1-16

  Kao, Chi H J ^a   Bishop, Karen S ^a   Xu, Yuanye ^a   Han, Dug Yeo ^a   Murray, Pamela M ^a   Marlow, Gareth J ^a   Ferguson, Lynnette R ^a  

^a THE UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

DU145; Ganoderma lucidum; Microarray; PC3; Prostate cancer; Western blot

Indexed keywords

AZATHIOPRINE; GANODERMA LUCIDUM EXTRACT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG ISOLATION; DU145 CELL LINE; GANODERMA LUCIDUM; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PC3 CELL LINE; PROSTATE CANCER CELL LINE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SAKE; SEPARATION TECHNIQUE; WESTERN BLOTTING; WHISKEY;

EID: 84992184197     PISSN: None     EISSN: 11786310     Source Type: Journal    
DOI: 10.1177/1178631018801448     Document Type: Erratum

References (76)

1. Paterson RR. Ganoderma-a therapeutic fungal biofactory. Phytochemistry. 2006; 67(18):1985-2001.
2. Kao CHJ, Jesuthasan AC, Bishop KS, Glucina MP, Ferguson LP. Anti-cancer activities of Ganoderma lucidum: active ingredients and pathways. FFHD. 2013;3(2):48-65.
3. Valverde ME, Hernández-Pérez T, Paredes-López O. Edible mushrooms: improving human health and promoting quality life. Int J Microbiol. 2015;2015: 376387.
4. Lin ZB. Cellular and molecular mechanisms of immuno-modulation by Ganoderma lucidum. J Pharmacol Sci. 2005;99(2):144-153.
5. Ko HH, Hung CF, Wang JP, Lin CN. Antiinflammatory triterpenoids and steroids from Ganoderma lucidum and G. tsugae. Phytochemistry. 2008;69(1): 234-239.
6. Sanodiya BS, Thakur GS, Baghel RK, Prasad GB, Bisen PS. Ganoderma lucidum: a potent pharmacological macrofungus. Curr Pharm Biotechnol. 2009;10(8): 717-742.
7. Jong SC, Birmingham JM. Medicinal benefits of the mushroom Ganoderma. Adv Appl Microbiol. 1992;37:101-134.
8. Wachtel-Galor S, Yuen J, Buswell JA, Benzie IFF. Ganoderma lucidum (Lingzhi or Reishi): a medicinal mushroom. In: Benzie IFF, Wachtel-Galor S, eds. Herbal Medicine: Biomolecular and Clinical Aspects. 2nd ed. Boca Raton: CRC Press; 2011:53-76.
9. Smina TP, De S, Devasagayam TPA, Adhikari S, Janardhanan KK. Ganoderma lucidum total triterpenes prevent radiation-induced DNA damage and apoptosis in splenic lymphocytes in vitro. Mutat Res Genet Toxicol Environ Mutagen. 2011; 726(2):188-194.
10. Zhang W, Tao J, Yang X, et al. Antiviral effects of two Ganoderma lucidum triterpenoids against enterovirus 71 infection. Biochem Biophys Res Commun. 2014; 449(3):307-312.
11. Kim YS, Eo SK, Oh KW, Lee C, Han SS. Antiherpetic activities of acidic protein bound polysacchride isolated from Ganoderma lucidum alone and in combinations with interferons. J Ethnopharmacol. 2000;72(3):451-458.
12. Zhang J, Tang Q, Zimmerman-Kordmann M, Reutter W, Fan H. Activation of B lymphocytes by GLIS, a bioactive proteoglycan from Ganoderma lucidum. Life Sci. 2002;71(6):623-638.
13. Lu H, Kyo E, Uesaka T, Katoh O, Watanabe H. A water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi) mycelia suppresses azoxymethane-induction of colon cancers in male F344 rats. Oncol Rep. 2003;10(2): 375-379.
14. Thyagarajan A, Jedinak A, Nguyen H, et al. Triterpenes from Ganoderma lucidum induce autophagy in colon cancer through the inhibition of p38 mitogenactivated kinase (p38 MAPK). Nutr Cancer. 2010;62(5):630-640.
15. Gao Y, Zhang R, Zhang J, et al. Study of the extraction process and in vivo inhibitory effect of ganoderma triterpenes in oral mucosa cancer. Molecules. 2011; 16(7):5315-5332.
16. Niksic M, Nikicevic N, Tesevic V, Klaus A. Evaluation of Alcoholic Beverages Based on Ganoderma lucidum (Curt.: Fr.) P. Karst. Extract. Int J Med Mushrooms. 2001;3(2-3):1.
17. Cheng S, Sliva D. Ganoderma lucidum for cancer treatment: we are close but still not there. Integr Cancer Ther. 2015;14(3):249-257.
18. Liu RM, Li YB, Zhong JJ. Cytotoxic and pro-apoptotic effects of novel ganoderic acid derivatives on human cervical cancer cells in vitro. Eur J Pharmacol. 2012;681(1-3):23-33.
19. Liu RM, Zhong JJ. Ganoderic acid Mf and S induce mitochondria mediated apoptosis in human cervical carcinoma HeLa cells. Phytomedicine. 2011;18(5): 349-355.
20. Jiang J, Grieb B, Thyagarajan A, Sliva D. Ganoderic acids suppress growth and invasive behavior of breast cancer cells by modulating AP-1 and NF-kappaB signaling. Int J Mol Med. 2008;21(5):577-584.
21. Wu GS, Song YL, Yin ZQ, et al. Ganoderiol A-enriched extract suppresses migration and adhesion of MDA-MB-231 cells by inhibiting FAK-SRCpaxillin cascade pathway. PLoS One. 2013;8(10):e76620.
22. Loganathan J, Jiang J, Smith A, et al. The mushroom Ganoderma lucidum suppresses breast-to-lung cancer metastasis through the inhibition of pro-invasive genes. Int J Oncol. 2014;44(6):2009-2015.
23. Li A, Shuai X, Jia Z, et al. Ganoderma lucidum polysaccharide extract inhibits hepatocellular carcinoma growth by downregulating regulatory T cells accumulation and function by inducing microRNA-125b. J Transl Med. 2015; 13:100.
24. Kim H, Suh HJ, Kang CM, Lee KH, Hwang JH, Yu KW. Immunological activity of ginseng is enhanced by solid-state culture with Ganoderma lucidum mycelium. J Med Food. 2014;17(1):150-160.
25. Wang SY, Hsu ML, Hsu HC, et al. The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. Int J Cancer. 1997;70(6):699-705.
26. Chen WC, Hau DM. Effects of Ganoderma lucidum on cellular immunocompetence in gamma-irradiated mice. Phytother Res. 1995;9(7):533-535.
27. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-E386.
28. Litvinov IV, Antony L, Dalrymple SL, Becker R, Cheng L, Isaacs JT. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. Prostate. 2006;66(12):1329-1338.
29. Yang G, Yang L, Zhuang Y, Qian X, Shen Y. Ganoderma lucidum polysaccharide exerts anti-tumor activity via MAPK pathways in HL-60 acute leukemia cells. J Recept Signal Transduct Res. 2014;20:1-8.
30. Martinez-Montemayor MM, Acevedo RR, Otero-Franqui E, Cubano LA, Dharmawardhane SF. Ganoderma lucidum (Reishi) inhibits cancer cell growth and expression of key molecules in inflammatory breast cancer. Nutr Cancer. 2011; 63(7):1085-1094.
31. Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood. 1999;93(9):2817-2823.
32. Hawwa AF, Millership JS, Collier PS, et al. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br J Clin Pharmacol. 2008;66(4):517-528.
33. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990;82(13):1107-1112.
34. Auer H, Newsom DL, Kornacker K. Expression profiling using affymetrix GeneChip microarrays. Methods Mol Biol. 2009;509:35-46.
35. R Development Core Team (2010), R: A Language and Environment for Statistical Computing. Vienna, Austria: the R Foundation for Statistical Computing. ISBN: 3-900051-07-0. Available online at http://www.R-project.org/.
36. Smyth GK. Limma: linear models for microarray data. In: Gentleman R, Carey V, Huber W, Irizarry R, Dudoit S, eds. Bioinformatics and Computational Biology Solutions Using R and Bioconductor. New York: Springer; 2005:397-420.
37. R Development Core Team (2013), R: A Language and Environment for Statistical Computing. Vienna, Austria: the R Foundation for Statistical Computing. ISBN: 3-900051-07-0. Available online at http://www.R-project.org/.
38. Fried JY, van Iersel MP, Aladjem MI, Kohn KW, Luna A. PathVisio-faceted search: an exploration tool for multi-dimensional navigation of large pathways. Bioinformatics. 2013;29(11):1465-1466.
39. Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Dev Cell. 2008;14(2):159-169.
40. Duthie GG, Pedersen MW, Gardner PT, et al. The effect of whisky and wine consumption on total phenol content and antioxidant capacity of plasma from healthy volunteers. Eur J Clin Nutr. 1998;52(10):733-736.
41. Pandey KB, Rizvi SI. Plant polyphenols as dietary antioxidants in human health and disease. Oxid Med Cell Longev. 2009;2(5):270-278.
42. Sheng S. The urokinase-type plasminogen activator system in prostate cancer metastasis. Cancer Metastasis Rev. 2001;20(3-4):287-296.
43. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-674.
44. Cherian E, Sudheesh NP, Janardhanan KK, Patani G. Free-radical scavenging and mitochondrial antioxidant activities of Reishi-Ganoderma lucidum (Curt: Fr) P. Karst and arogyapacha-trichopus zeylanicus gaertn extracts. J Basic Clin Physiol Pharmacol. 2009;20(4):289-307.
45. Ajith TA, Sudheesh NP, Roshny D, Abishek G, Janardhanan KK. Effect of Ganoderma lucidum on the activities of mitochondrial dehydrogenases and complex I and II of electron transport chain in the brain of aged rats. Exp Gerontol. 2009; 44(3):219-223.
46. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003;36(3): 131-149.
47. Chan KS, Koh CG, Li HY. Mitosis-targeted anti-cancer therapies: where they stand. Cell Death Dis. 2012;3:e411.
48. Ouyang L, Shi Z, Zhao S, et al. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 2012; 45(6):487-498.
49. Guerra-Vladusic FK, Scott G, Weaver V, et al. Constitutive expression of Heregulin induces apoptosis in an erbB-2 overexpressing breast cancer cell line SKBr-3. Int J Oncol. 1999;15(5):883-892.
50. Blagosklonny MV. Analysis of FDA approved anticancer drugs reveals the future of cancer therapy. Cell Cycle. 2004;3(8):1035-1042.
51. Kazma R, Mefford JA, Cheng I, et al. Association of the innate immunity and inflammation pathway with advanced prostate cancer risk. PLoS One. 2012;7(12): e51680.
52. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-899.
53. Kennedy R, Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev. 2008;222:129-144.
54. Bendas G, Borsig L. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int J Cell Biol. 2012;2012:676731.
55. Schettino C, Bareschino MA, Rossi A, et al. Targeting angiogenesis for treatment of NSCLC brain metastases. Curr Cancer Drug Targets. 2012;12(3):289-299.
56. Marchong MN, Yurkowski C, Ma C, Spencer C, Pajovic S, Gallie BL. Cdh11 acts as a tumor suppressor in a murine retinoblastoma model by facilitating tumor cell death. PLoS Genet. 2010;6(4):e1000923.
57. Kubota Y. Tumor angiogenesis and anti-angiogenic therapy. Keio J Med. 2012; 61(2):47-56.
58. Cathcart MC, O'Byrne KJ, Reynolds JV, O'Sullivan J, Pidgeon GP. COXderived prostanoid pathways in gastrointestinal cancer development and progression: novel targets for prevention and intervention. Biochim Biophys Acta. 2012;1825(1):49-63.
59. Yeh S, Hu YC, Rahman M, et al. Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proc Natl Acad Sci U S A. 2000;97(21):11256-11261.
60. Castro E, Eeles R. The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl. 2012;14(3):409-414.
61. Klein HL. The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair. 2008;7(5):686-693.
62. Qidwai MT, Jamal F, Singh D, Sharma RK. Factors modifying transcriptional regulation of signaling genes have putative role in tumor development and progression in humans. Med Hypotheses. 2012;79(6):805-812.
63. Gebhardt C, Nemeth J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol. 2006;72(11):1622-1631.
64. Grebhardt S, Veltkamp C, Strobel P, Mayer D. Hypoxia and HIF-1 increase S100A8 and S100A9 expression in prostate cancer. Int J Cancer. 2012;131(12): 2785-2794.
65. Hong KJ, Dunn DM, Shen CL, Pence BC. Effects of Ganoderma lucidum on apoptotic and anti-inflammatory function in HT-29 human colonic carcinoma cells. Phytother Res. 2004;18(9):768-770.
66. Joseph S, Sabulal B, George V, Antony KR, Janardhanan KK. Antitumor and anti-inflammatory activities of polysaccharides isolated from Ganoderma lucidum. Acta Pharm. 2011;61(3):335-342.
67. Lin JM, Lin CC, Chiu HF, Yang JJ, Lee SG. Evaluation of the anti-inflammatory and liver-protective effects of anoectochilus formosanus, Ganoderma lucidum and Gynostemma pentaphyllum in rats. Am J Chin Med. 1993;21(1):59-69.
68. Patani N, Douglas-Jones A, Mansel R, Jiang W, Mokbel K. Tumour suppressor function of MDA-7/IL-24 in human breast cancer. Cancer Cell Int. 2010;10:29.
69. Murtas D, Maric D, De Giorgi V, et al. IRF-1 responsiveness to IFN-gamma predicts different cancer immune phenotypes. Br J Cancer. 2013;109(1):76-82.
70. Boudny V, Kovarik J. JAK/STAT signaling pathways and cancer. Janus kinases/signal transducers and activators of transcription. Neoplasma. 2002;49(6):349-355.
71. Sauane M, Gupta P, Lebedeva IV, et al. N-glycosylation of MDA-7/IL-24 is dispensable for tumor cell-specific apoptosis and "bystander" antitumor activity. Cancer Res. 2006;66(24):11869-11877.
72. Sauane M, Gopalkrishnan RV, Lebedeva I, et al. Mda-7/IL-24 induces apoptosis of diverse cancer cell lines through JAK/STAT-independent pathways. J Cell Physiol. 2003;196(2):334-345.
73. Schwartz JL, Shajahan AN, Clarke R. The role of interferon regulatory factor-1 (IRF1) in overcoming antiestrogen resistance in the treatment of breast cancer. Int J Breast Cancer. 2011;2011:912102.
74. Li YJ, Liu G, Li Y, et al. mda-7/IL-24 expression inhibits breast cancer through up-regulation of growth arrest-specific gene 3 (gas3) and disruption of beta1 integrin function. Mol Cancer Res. 2013;11(6):593-603.
75. Xu S, Oshima T, Imada T, et al. Stabilization of MDA-7/IL-24 for colon cancer therapy. Cancer Lett. 2013:421-430.
76. Hu Y, Park-Min KH, Yarilina A, Ivashkiv LB. Regulation of STAT pathways and IRF1 during human dendritic cell maturation by TNF-alpha and PGE2. J Leukoc Biol. 2008;84(5):1353-1360.